Ramaswamy Govindan

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 37%
3. Neoplasms 30%
4. Survival 19%
5. Pemetrexed 18%
6. Carboplatin 18%
7. Small Cell Lung Carcinoma 16%
8. Drug Therapy 16%
9. Therapeutics 14%
10. Mutation 13%
11. Atlases 12%
12. Genome 12%
13. Adenocarcinoma of Lung 11%
14. Docetaxel 11%
15. Paclitaxel 10%
16. Bevacizumab 9%
17. ErbB Receptors 9%
18. Cisplatin 8%
19. Platinum 8%
20. Progression-Free Survival 7%
21. Erlotinib Hydrochloride 7%
22. Radiotherapy 7%
23. Squamous Cell Carcinoma 7%
24. Medical Oncology 6%
25. Safety 6%
26. Recurrence 6%
27. Neoplasm Metastasis 6%
28. Smokers 6%
29. Gefitinib 6%
30. Lung 6%
31. Positron-Emission Tomography 5%
32. Thorax 5%
33. Irinotecan 5%
34. Radiation 5%
35. Adjuvant Chemotherapy 5%
36. Guidelines 5%
37. Clinical Trials 5%
38. Squamous Cell Neoplasms 5%
39. High-Throughput Nucleotide Sequencing 5%
40. Genes 5%
41. roniciclib 5%
42. CH5424802 5%
43. Protein-Tyrosine Kinases 5%
44. Etoposide 5%
45. Cetuximab 5%
46. Adenocarcinoma 5%
47. Crizotinib 5%
48. Maximum Tolerated Dose 5%